People: Zogenix Inc (ZGNX.OQ)

ZGNX.OQ on NASDAQ Stock Exchange Global Market

9:20pm IST
Change (% chg)

$0.20 (+0.48%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Galer, Bradley 

Dr. Bradley S. Galer, M.D. is the Executive Vice President and Chief Medical Officer of Zogenix, Inc. Dr. Galer has served as our Executive Vice President and Chief Medical Officer since December 2013. Prior to joining the company, Dr. Galer served as President of the Pain Group at Nuvo Research, Inc., a specialty pharmaceutical company with three commercialized topically delivered pain products from December 2009 to December 2013. In this position, he oversaw the strategy and operations of the Pain Group, including its commercialization, drug development activities, business development and licensing opportunities and liaising with partners. Prior to joining Nuvo, Dr. Galer was employed at Endo Pharmaceuticals Inc., as Senior Medical Officer and Group Vice President, Scientific Affairs from August 2002 to October 2005, where he was responsible for the departments of Clinical and Biostatistics, Medical Affairs, Pharmacovigilance, Medical Liaison and Medical Information. He and his team provided clinical and scientific leadership for the development and marketing of analgesic and migraine products, including Lidoderm, Percocet, Opana, Opana ER and Frova. Dr. Galer has also held numerous other industry positions, along with academic and clinical appointments. He has published over 200 articles on pain management in peer review journals and textbooks. Dr. Galer received his medical doctorate and a neurology residency from Albert Einstein in New York and two Pain Fellowships, at Memorial Sloane-Kettering in New York and University of California San Francisco, as well as headache training at Montefiore Headache Clinic in New York and University of California San Francisco.

Basic Compensation

Total Annual Compensation, USD 587,948
Restricted Stock Award, USD 266,563
Long-Term Incentive Plans, USD --
All Other, USD 1,700,360
Fiscal Year Total, USD 2,554,870

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Cam Garner


Stephen Farr


Michael Smith


Gail Farfel


Bradley Galer


Ashish Sagrolikar

As Of  31 Dec 2018